New data has shown that there were no cervical cancer deaths in England among women aged 20 to 24 over a four-year period. The findings, published in the Lancet journal, have been described as an extraordinary statistic and a major breakthrough. Researchers attribute the result largely to the growing uptake of the HPV vaccine among young people.
According to the data, around 90% of women in that age group had received the HPV vaccine. The jab is offered to children at around the age of 12 or 13 through school-based programmes. It protects against the human papillomavirus, an infection that is linked to the development of cervical cancer later in life.
Health experts say the evidence shows the vaccine is saving lives. It is estimated that around 200 deaths from cervical cancer have already been prevented since the programme began. That figure is expected to rise further as more generations who received the vaccine grow older.
Specialists stress that the vaccine is most effective when it is given before a person has been exposed to HPV, which is why it is offered to children between the ages of 11 and 13. They describe the jab as safe and effective, and point to the new research as clear evidence of its impact on public health.
Experts caution, however, that the vaccine is only part of the picture. Cervical screening remains an important tool for detecting problems early, and together the two approaches could dramatically reduce cervical cancer. People are urged to attend their screening appointments and to be aware of any unusual symptoms in their body.
There are concerns about uptake, partly because the school-based programme was disrupted during the COVID period, and because of some hesitancy among parents. Officials say anyone who missed the vaccine at school, or who was home-schooled, can still receive it for free up to the age of 25 through a GP, school nurse or immunisation team.
The findings come amid a wider debate in Britain about cancer care and screening, including calls for more regular checks for other cancers. While some campaigners describe the overall picture as mixed, the cervical cancer data has been welcomed as strong and encouraging evidence that a long-running public health programme is working.